Clostridium Difficile News and Research RSS Feed - Clostridium Difficile News and Research

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.
U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Nearly half of American hospitals aren't taking key steps to prevent a kind of gut infection that kills nearly 30,000 people annually and sickens hundreds of thousands more - despite strong evidence that such steps work, according to a new study. [More]
Focus Diagnostics announces FDA clearance for Simplexa Group A Strep Direct Kit

Focus Diagnostics announces FDA clearance for Simplexa Group A Strep Direct Kit

Focus Diagnostics, the clinical-laboratory products business of Quest Diagnostics, today announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit. Simplexa Group A Strep Direct is a real-time polymerase chain reaction assay for the detection of Group A Streptococcus bacteria directly from throat swabs. [More]
Infectious diseases experts release new guidance to avoid infections during hospital visits

Infectious diseases experts release new guidance to avoid infections during hospital visits

Leading infectious diseases experts have released new guidance for healthcare facilities looking to establish precautions for visitors of patients with infectious diseases. The guidance looks to reduce the potential for healthcare visitors in spreading dangerous bacteria within the healthcare facility and community. [More]
Fecal microbiota transplantation more successful for treating Clostridium difficile infections

Fecal microbiota transplantation more successful for treating Clostridium difficile infections

Distasteful though it sounds, the transplantation of fecal matter is more successful for treating Clostridium difficile infections than previously thought. [More]
Study finds C. difficile infection increases hospital readmission rates

Study finds C. difficile infection increases hospital readmission rates

Patients with Clostridium difficile infection (CDI) are twice as likely to be readmitted to the hospital as patients without the deadly diarrheal infection, according to a study published in the April issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology. [More]
Aggressive campaign to cut unnecessary use of antibiotics helps reduce drug-resistant bacteria

Aggressive campaign to cut unnecessary use of antibiotics helps reduce drug-resistant bacteria

An aggressive campaign to reduce the unnecessary use of antibiotics has helped cut the rate of infection with a dangerous drug-resistant bacteria at The Valley Hospital by nearly 40 percent. [More]
Deadly C. difficile affected almost half a million in the U.S over one year

Deadly C. difficile affected almost half a million in the U.S over one year

The deadly bug Clostridium difficile (C. diff) infected more than 450,000 people in the U.S in a single year, according to new research funded by the Centers for Disease Control and Prevention (CDC). [More]
Researchers reveal how C. difficile wreaks havoc on guts, causes life-threatening diseases

Researchers reveal how C. difficile wreaks havoc on guts, causes life-threatening diseases

In a new paper in the journal Infection and Immunity, the researchers lay out for the first time exactly how C. difficile wreaks havoc on the guts of animals in a short time, and causes severe diarrhea and life-threatening disease in humans. [More]
Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
Risks and benefits of fecal microbiota transplant

Risks and benefits of fecal microbiota transplant

A woman successfully treated for a recurrent Clostridium difficile infection with stool from an overweight donor rapidly gained weight herself afterwards, becoming obese, according to a case report published in the new journal Open Forum Infectious Diseases. [More]
Bathing critically ill patients with chlorhexidine wipes does not prevent ICU infections

Bathing critically ill patients with chlorhexidine wipes does not prevent ICU infections

Vanderbilt University Medical Center researchers have found that bathing critically ill patients with disposable chlorhexidine cloths did not decrease the incidence of health care-associated infections when compared to less expensive nonantimicrobial cloths, according to a study appearing online in JAMA this week. [More]
MGB Biopharma provides update on business performance for 2014

MGB Biopharma provides update on business performance for 2014

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, provides an update on its business performance for 2014. MGB Biopharma is developing a pipeline of novel antimicrobials that puts it at the forefront of addressing the major global problem of antimicrobial resistance. [More]
Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics, today announced that its Simplexa Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter. [More]
New Mayo Clinic study shows impact of long-term use of proton pump inhibitors

New Mayo Clinic study shows impact of long-term use of proton pump inhibitors

Before reaching for that daily antacid, you might consider what it's doing to the trillions of bugs living in your gut. A new Mayo Clinic study in the open access journal Microbiome shows that people who regularly take proton pump inhibitors (PPIs) have less diversity among their gut bacteria, putting them at increased risk for infections like clostridium difficile and pneumonia, in addition to vitamin deficiencies and bone fractures. [More]
MUHC study examines effect of regular re-evaluation of antibiotic use on cost, C. difficile infection rates

MUHC study examines effect of regular re-evaluation of antibiotic use on cost, C. difficile infection rates

Resistance to antibiotics is an important health concern that affects both the spread of infections, like Clostridium difficile, and the medication budget. Researchers at the McGill University Health Centre examined the effectiveness of adopting an antibiotic "time-out" during treatment, which involves regularly re-evaluating the treatment strategy as the clinical situation evolves. [More]
Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014. [More]

Study shows potential of treating recurrent CDI with frozen fecal matter

A preliminary study has shown the potential of treating recurrent Clostridium difficile infection (a bacterium that is one of the most common causes of infection of the colon) with oral administration of frozen encapsulated fecal material from unrelated donors, which resulted in an overall rate of resolution of diarrhea of 90 percent, according to a study published in JAMA. [More]
RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

Rebiotix Inc. announced today that results of the Phase 2 PUNCH CD Study found that the overall efficacy of RBX2660 in the treatment of recurrent Clostridium difficile infection was 87.1%. The study also found that administration of RBX2660 was well-tolerated and demonstrated satisfactory safety in the 60-day interim analysis. [More]
Study finds that hospitalized patients wash their hands infrequently

Study finds that hospitalized patients wash their hands infrequently

Hospital visitors and staff are greeted with hand sanitizer dispensers in the lobby, by the elevators and outside rooms as reminders to wash their hands to stop infections, but just how clean are patients' hands? [More]
Advertisement
Advertisement